In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer

Vaccine

Volumn 28, Issue 1, 2009, Pages 120-131

  Gupta, Shishir Kumar ^a   Singh, Archana ^a   Srivastava, Mugdha ^a   Gupta, Shailendra K ^b   Akhoon, Bashir Akhlaq ^c  

^a Society for Biological Research and Rural Development   (India)

^b CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^c SHRI MATA VAISHNO DEVI UNIVERSITY   (India)

Author keywords

Cervical cancer; Clinical informatics; DNA vaccine; HPV; Vaccine designing

Indexed keywords

CAPSID PROTEIN; DNA VACCINE; EPITOPE; PLASMID VECTOR; VIRUS VACCINE;

ARTICLE; CODON; CONSENSUS; DNA SEQUENCE; DNA VECTOR; IMMUNOGENICITY; IMMUNOSTIMULATION; MOLECULAR CLONING; MOLECULE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHYLOGENY; PLASMID; PRIORITY JOURNAL; TECHNIQUE; UTERINE CERVIX CANCER; VIRUS STRAIN; WART VIRUS;

ANTIGENS, VIRAL; CANCER VACCINES; CAPSID PROTEINS; CLONING, MOLECULAR; CLUSTER ANALYSIS; CPG ISLANDS; EPITOPES; FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; OPEN READING FRAMES; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHYLOGENY; SEQUENCE ALIGNMENT; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

EID: 70849098763     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.095     Document Type: Article

References (75)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 18 major cancers in 1985. Int J Cancer 54 (1993) 594-606
2. http://www.cdc.gov/STD/HPV/STDFact-HPV.htm
3. Mũnoz N., Castellsagué X., Berrington A., de González A.B., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 21 24 (Suppl. 3) (2006) S1-10
4. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
5. Meijer C.J.L.M., Heideman A.M.D., Berkhof H., and Snijders J.F.P. Prevention of cervical cancer: where immunology meets diagnostics. Immunol Lett 122 2 (2009) 126-127
6. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 6 (2003) 518-527
7. Flores E.R., Allen-Hoffmann B.L., Lee D., Sattler C.A., and Lambert P.F. Establishment of the Human Papillomavirus Type 16 (HPV-16) life cycle in an Immortalized Human Foreskin Keratinocyte Cell Line. Virology 262 2 (1999) 344-354
8. Brinton L.A. Epidemiology of cervical cancer-overview. IARC Sci Publ 119 (1992) 3-23
9. Schiffman M.H., and Brinton L.A. The epidemiology of cervical carcinogenesis. Cancer 76 (1995) 1888-1901
10. Franco E.L. Epidemiology of uterine cancers. In: Meisels A., and Morin C. (Eds). Cytopathology of the uterus. 2nd ed. (1997), American Society of Clinical Pathologists, Chicago 301-324
11. Winkelstein W. Smoking and cervical cancer: current status-a review. Am J Epidemiol 131 (1990) 945-957
12. Schiffman M.H., Brinton L.A., Devesa S.S., and Fraumeni Jr. J.F. Cervical cancer. In: Schottenfeld D., and Fraumeni Jr. J.F. (Eds). Cancer epidemiology and prevention (1996), Oxford University Press, New York 1090-1116
13. Palmer K.E., Benko A., Doucette S.A., Cameron T.I., Foster T., Hanley K.M., et al. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine 24 26 (2006) 5516-5525
14. Einstein M.H. Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. Cancer Immunol Immunother 57 4 (2008) 443-451
15. Gambhira R., Gravitt P.E., Bossis I., Stern P.L., Viscidi R.P., and Roden R.B. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 66 23 (2006) 11120
16. Wright T., Bosch F., Franco E., Cuzick J., Schiller J., Garnett G., et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 24 3 (2006) 251-261
17. Zimet G.D., Shew M.L., and Kahn J.A. Appropriate use of cervical cancer vaccine. Annu Rev Med 59 (2008) 223-236
18. Zimet G.D., Liddon N., Rosenthal S.L., Lazcano-Ponce E., and Allen B. Chapter 24: psychosocial aspects of vaccine acceptability. Vaccine 24 3 (2006) 201-209
19. National Board of Health, and Danish Centre for Health Technology Assessment. Reduction in the risk of cervical cancer by vaccination against HPV-a health technology assessment 9 (1) (2007), Danish Center for Health Technology Assessment. http://www.dacehta.dk/ [Retrieved 17 August 2007]
20. Varsani A., Williamson A.L., de Villiers D., Becker I., Christensen N.D., and Rybicki E.P. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 77 15 (2003) 8386-8393
21. Kondo K., Ishii Y., Ochi H., Matsumoto T., Yoshikawa H., and Kanda T. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358 (2007) 266-272
22. Roden R.B.S., Yutzy W.H., Fallon R., Inglis S., Lowy D.R., and Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270 (2000) 254-257
23. LI G.F., Wang Y., Zhang Z.S., Wang X.J., JI M.J., Zhu X., et al. Identification of immunodominant Th1-type T cell epitopes from Schistosoma japonicum 28 kDa glutathione-S-transferase, a vaccine candidate. Acta Biochim Biophys Sinica 37 11 (2005) 751-758
24. Reche P.A., Glutting J.P., Zhang H., and Reinherz E.L. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 56 (2004) 405-419
25. Harish N., Gupta R., Agarwal P., Scaria V., and Pillai B. DyNAVacS: an integrative tool for optimized DNA vaccine design. Nucleic Acids Res 34 (2008) 264-266
26. Lasaro M.O., and Ertl H.C.J. Human papillomavirus-associated cervical cancer: prophylactic and therapeutic vaccines. Gene Ther Mol Biol 8 (2004) 291-306
27. Shannon C.E. The mathematical theory of communication. Bell Syst Tech J 27 (1948) pp. 379-423 and 623-656
28. Huynh-Hoa B., John S., Wei Li, Nicolas F., and Alessandro S. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinform 8 361 (2007)
29. http://immunax.dfci.harvard.edu/Tools/rankpep_help.html
30. Alfredo F., Rosalba G., Giuseppe P., Alfredo P., Cinzia D.P., Michele P., et al. Sequence similarity is more relevant than species specificity in probabilistic backtranslation. BMC Bioinform 8 58 (2007)
31. Peter R., Ian L., and Alan B. EMBOSS: the European molecular biology open suite. Trends in Genetics 16 6 (2000) 276-277
32. Kuljeet S.S., Sunil P., Souvik M., and Beena P. GASCO: genetic algorithm simulation for codon optimization. In Silico Biol 8 2 (2008) 187-192
33. Nakamura Y., Gojobori T., and Ikemura T. Codon usage tabulated from the international DNA sequence databases. Nucleic Acids Res 26 1 (1998) 334-335
34. Frappat L., Minichini C., Sciarrino A., and Sorba P. Universality and Shannon entropy of codon usage. Phys Rev E 68 (2003) 061910
35. Arthur M.K., Ae-Kyung Y., Joachim S., and Heather L.D. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 6 1 (1998) 23-27
36. Klinman D.M., Yamshchikov G., and Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158 8 (1997) 3635-3639
37. Dolenc I., Seemuller E., and Baumeister W. Decelerated degradation of short peptides by the 20S proteasome. FEBS Lett 434 (1998) 357-361
38. Chiang H.L., Terlecky S.R., Plant C.P., and Dice J.F. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science 246 4928 (1989) 382-385
39. Richard A.G., Thomas J.K., Barbara A.O., and Janis K. Kuby Immunol. 5th ed. (2000), W.H. Freeman & Company Publications
40. http://www.invitrogen.com/site/us/en/home.html
41. Donna L.M., and Kristala J.P. Design of plasmid DNA constructs for vaccines. In: Saltzman W.M., Shen H., and Brandsma J.L. (Eds). Methods in molecular medicine, DNA vaccines: methods and protocols. 2nd ed. vol. 127 (2006), Humana Press 11-22
42. Zhang Q., Wang P., Kim Y., Andersen P.H., Beaver J., Bourne P.E., et al. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res 36 (2008) 513-518
43. Lundegaard C., Lamberth K., Harndahl M., Buus S., Lund O., and Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse, and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36 (2008) 509-512
44. Lundegaard C., Nielsen M., and Lund O. The validity of predicted T-cell epitopes. Trends Biotechnol 24 (2006) 537-538
45. Lundegaard C., Lund O., and Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24 (2008) 1397-1398
46. Nielsen M., Lundegaard C., Worning P., Lauemøller S.L., Lamberth K., Buus S., et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12 (2003) 1007-1017
47. Buus S., Lauemøller S.L., Worning P., Kesmir C., Frimurer T., Corbet S., et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 62 (2003) 378-384
48. Wang P., Sidney J., Dow C., Mothé B., Sette A., and Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4 4 (2008) 1000048
49. Blythe M.J., and Flower D.R. Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci 14 (2005) 246-248
50. Greenbaum J.A., Andersen P.H., Blythe M., Bui H.-H., Cachau R.E., Crowe J., et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit 20 (2007) 75-82
51. von Goethe J.W. Vaccines: structural approaches. In: Flower D.R. (Ed). Bioinformatics for vaccinology (2008), Wiley-Blackwell Publication, UK 217-254
52. Rajkannan R., and Malar E.J.P. Docking of B-cell epitope antigen to specific hepatitis B antibody. J Chem Sci 119 5 (2007) 553-558
53. Maupetit J., Derreumaux P., and Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res 37 (2009) 498-503
54. Maupetit J., Derreumaux P., and Tuffery P. A fast and accurate method for large-scale de novo peptide structure prediction. J Comput Chem (2009)
55. Kaur H., Garg A., and Raghava G.P. PEPstr: a de novo method for tertiary structure prediction of small bioactive peptides. Protein Pept Lett 14 7 (2007) 626-631
56. Camproux A.C., Tuffery P., Chevrolat J.P., Boisvieux J.F., and Hazout S. Hidden Markov model approach for identifying the modular framework of the protein backbone. Protein Eng 12 12 (1999) 1063-1073
57. Camproux A.C., Gautier R., and Tuffery P. A hidden markov model derived structural alphabet for proteins. J Mol Biol 339 June (3) (2004) 591-605
58. Tuffery P., Guyon F., and Derreumaux P. Improved greedy algorithm for protein structure reconstruction. J Comput Chem 26 5 (2005) 506-513
59. Tuffery P., and Derreumaux P. Dependency between consecutive local conformations helps assemble protein structures from secondary structures using Go potential and greedy algorithm. Proteins 61 4 (2005) 732-740
60. Maupetit J., Tuffery P., and Derreumaux P. A coarse-grained protein force field for folding and structure prediction. Proteins 69 2 (2007) 394-408
61. Litwin S., and Jores R. In: Perelson A.S., and Weisbuch G. (Eds). In theoretical and experimental insights into immunology (1992), Springer-Verlag, Berlin
62. Gupta S.K., Singh A., and Srivastava M. Designing of drug for removal of methylation from Tcf21 gene in lung cancer. Online J Bioinform 11 1 (2009) 149-155
63. Sasaki S., Takeshita F., Xin K.Q., Ishii N., and Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 31 (2003) 243-254
64. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273 (1996) 352-354
65. James A.W., Jeremy L., Lance J., and Clague H. pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids. Vaccine 24 (2006) 4671-4676
66. Zhuhui H., Sateesh K., Aruna P., and Siba K.S. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J Virol 77 16 (2003) 8676-8685
67. Jiang W., Ren L., and Jin N. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-α. J Virol Method 146 (2007) 266-273
68. Paterna J.C., and Bũeler H. Recombinant adeno-associated virus vector design and gene expression in the mammalian brain. Methods 28 (2002) 208-218
69. Baskar J.F., Smith P.P., Ciment G.S., Hoffmann S., Tucker C., Tenney D.J., et al. J Virol 70 (1996) 3215-3226
70. Baskar J.F., Smith P.P., Nilaver G., Jupp R.A., Hoffmann S., Peffer N.J., et al. J Virol 70 (1996) 3207-3214
71. Jathoul A.P., Holley J.L., and Garmory H.S. Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine 22 (2004) 3942-3946
72. Bartlett R.J., Secore S.L., Singer J.T., Bodo M., Sharma K., and Ricordi C. Long-term expression of a fluorescent reporter gene via direct injection of plasmid vector into mouse skeletal muscle: comparison of human creatine kinase and CMV promoter expression levels in vivo. Cell Transplant 5 3 (1996) 411-419
73. Byun H.M., Suh D., Jeong Y., Wee H.S., Kim J.M., Ko J.J., et al. Plasmid vectors harboring cellular promoters can induce prolonged gene expression in hematopoietic and mesenchymal progenitor cells. Biochem Biophys Res Commun 332 (2005) 518-523
74. Berzofsky J.A. Intrinsic and extrinsic factors in protein antigenic structure. Science 229 (1985) 932-940
75. Hitzeroth I.I., Passmore J.A.S., Shephard E., Stewart D., Müllerd M., Williamson A.L., et al. Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine (2009)